Oncology and Hematology - Global Oncology Academy

609-624 of 809

Treatment Intensification in HR+/HER2- EBC: Who and When?
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
Project Oncology®
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
Betsy O'Donnell, MD
- Betsy O'Donnell, MD
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Project Oncology®
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Betsy O'Donnell, MD
- Betsy O'Donnell, MD
Risk Stratification Models for Precursor Diseases in Multiple Myeloma
Risk Stratification Models for Precursor Diseases in Multiple Myeloma
Project Oncology®
Risk Stratification Models for Precursor Diseases in Multiple Myeloma
Betsy O'Donnell, MD
- Betsy O'Donnell, MD
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Shubham Pant, MD, MBBS; Ritu Salani, MD
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD
0.75 program credits
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Shubham Pant, MD, MBBS
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Shubham Pant, MD, MBBS
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
Shubham Pant, MD, MBBS; Ritu Salani, MD
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Ritu Salani, MD
0.75 program credits
- Ritu Salani, MD
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
Shubham Pant, MD, MBBS; Ritu Salani, MD
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD
0.75 credits 8 episodes
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Ritu Salani, MD
0.75 program credits
- Ritu Salani, MD
0.75 program credits
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Ritu Salani, MD
0.75 program credits
- Ritu Salani, MD
0.75 program credits
Diversity in HER2 Expression Among Gynecologic Cancers
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®
Diversity in HER2 Expression Among Gynecologic Cancers
Ritu Salani, MD
0.75 program credits
- Ritu Salani, MD
0.75 program credits
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
CME/CE
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
Justin Gainor, MD; Jacob Sands, MD
0.50 credits
- Justin Gainor, MD
- Jacob Sands, MD
0.50 credits
Uncovering New Biomarkers for RCC: A Review of Emerging Techniques
Uncovering New Biomarkers for RCC: A Review of Emerging Techniques
Project Oncology®
Uncovering New Biomarkers for RCC: A Review of Emerging Techniques
Jody Takemoto, PhD, MEd; David Braun
- Jody Takemoto, PhD, MEd
- David Braun
Enhancing HCC Outcomes Through Multidisciplinary Care
Enhancing HCC Outcomes Through Multidisciplinary Care
Project Oncology®
Enhancing HCC Outcomes Through Multidisciplinary Care
Charles Turck, PharmD, BCPS, BCCCP; Hannah Lee, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Hannah Lee, MD

39/11